Leitgeb C - Search Results

1

Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors.

Ludwig H, Fritz E, Leitgeb C, Krainer M, Kührer I, Sagaster P, Umek H. Ludwig H, et al. Among authors: leitgeb c. Ann Oncol. 1993 Feb;4(2):161-7. doi: 10.1093/oxfordjournals.annonc.a058423. Ann Oncol. 1993. PMID: 8448084 Free article.

2

Prediction of response to erythropoietin treatment in chronic anemia of cancer.

Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Ludwig H, et al. Among authors: leitgeb c. Blood. 1994 Aug 15;84(4):1056-63. Blood. 1994. PMID: 7741835 Free article. Clinical Trial.

3

Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.

Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Leitgeb C, et al. Cancer. 1994 May 15;73(10):2535-42. doi: 10.1002/1097-0142(19940515)73:10<2535::aid-cncr2820731014>3.0.co;2-5. Cancer. 1994. PMID: 8174050 Clinical Trial.

4

Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma.

Ludwig H, Pecherstorfer M, Leitgeb C, Fritz E. Ludwig H, et al. Among authors: leitgeb c. Stem Cells. 1993 Sep;11(5):348-55. doi: 10.1002/stem.5530110502. Stem Cells. 1993. PMID: 8241947 Review.

5

Erythropoietin treatment of chronic anaemia of cancer.

Ludwig H, Leitgeb C, Fritz E, Krainer M, Kührer I, Kornek G, Sagaster P, Weissmann A. Ludwig H, et al. Among authors: leitgeb c. Eur J Cancer. 1993;29A Suppl 2:S8-12. doi: 10.1016/s0959-8049(05)80282-5. Eur J Cancer. 1993. PMID: 8398362 No abstract available.

6

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.

Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, Samonigg H, Kappeler AW, Fritz E. Ludwig H, et al. Among authors: leitgeb c. Cancer. 1995 Dec 1;76(11):2319-29. doi: 10.1002/1097-0142(19951201)76:11<2319::aid-cncr2820761121>3.0.co;2-u. Cancer. 1995. PMID: 8635038 Clinical Trial.

7

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weißmann A, Adam Z. Ludwig H, et al. Among authors: leitgeb c. Blood. 2014 Feb 13;123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13. Blood. 2014. PMID: 24227817 Free PMC article. Clinical Trial.

8

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M. Ludwig H, et al. Among authors: leitgeb c. Leukemia. 2017 Apr;31(4):997-1000. doi: 10.1038/leu.2017.5. Epub 2017 Jan 11. Leukemia. 2017. PMID: 28074071 Free PMC article. Clinical Trial. No abstract available.

9

Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.

Brämswig K, Ploner F, Martel A, Bauernhofer T, Hilbe W, Kühr T, Leitgeb C, Mlineritsch B, Petzer A, Seebacher V, Stöger H, Girschikofsky M, Hochreiner G, Ressler S, Romeder F, Wöll E, Brodowicz T. Brämswig K, et al. Among authors: leitgeb c. Anticancer Drugs. 2014 Aug;25(7):848-53. doi: 10.1097/CAD.0000000000000108. Anticancer Drugs. 2014. PMID: 24667659

10

[Quality of life and cytokines in oncological therapy].

Leitgeb C. Leitgeb C. Wien Med Wochenschr. 1998;148(18):424-6. Wien Med Wochenschr. 1998. PMID: 9888178 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

46 results

Search Page